S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:DRNA

Dicerna Pharmaceuticals Stock Forecast, Price & News

$38.22
0.00 (0.00%)
(As of 12/28/2021)
Add
Compare
Today's Range
$38.22
$38.22
50-Day Range
$21.19
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.8
30 days | 90 days | 365 days | Advanced Chart
Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals logo

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Headlines

DRNA Jan 2022 22.500 call
January 14, 2022 |  ca.finance.yahoo.com
DRNA Jul 2022 40.000 call(CONTR
January 14, 2022 |  ca.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRNA
Employees
302
Year Founded
N/A

Sales & Book Value

Annual Sales
$164.31 million
Book Value
$1.84 per share

Profitability

Net Income
$-112.75 million
Pretax Margin
-63.82%

Debt

Price-To-Earnings

Miscellaneous

Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/20/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

396th out of 1,415 stocks

Pharmaceutical Preparations Industry

183rd out of 682 stocks

Analyst Opinion: 2.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

Is Dicerna Pharmaceuticals a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 9 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Dicerna Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DRNA, but not buy additional shares or sell existing shares.
View analyst ratings for Dicerna Pharmaceuticals
or view top-rated stocks.

How has Dicerna Pharmaceuticals' stock price been impacted by Coronavirus?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DRNA stock has increased by 126.4% and is now trading at $38.22.
View which stocks have been most impacted by COVID-19
.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Dicerna Pharmaceuticals
.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to the consensus estimate of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. During the same quarter in the prior year, the company posted ($0.29) earnings per share.
View Dicerna Pharmaceuticals' earnings history
.

What price target have analysts set for DRNA?

10 brokers have issued 12 month target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $25.00 to $47.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $35.72 in the next year. This suggests that the stock has a possible downside of 6.5%.
View analysts' price targets for Dicerna Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $38.22.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals has a market capitalization of $2.99 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112.75 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

Dicerna Pharmaceuticals employs 302 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Where are Dicerna Pharmaceuticals' headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at (617) 621-8097, via email at [email protected], or via fax at 617-612-6298.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.